Novo Nordisk (NOVOB DC) takes legal action against Hims & Hers (HIMS) to protect patients from unsafe, knock-off Wegovy and Ozempic

Novo Nordisk's legal action against Hims & Hers is significant as it aims to protect its patented products, Wegovy and Ozempic, from what it claims are unsafe knock-offs.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Newsquawk Daily US Conference Calendar - 9th February 2026: ICE, IBKR, KKR, MRSH

US PRE-MARKET MOVERS: Mag-7, KR, NXST/TGNA, LLY, XYZ, META, CLF, BDX, HIMS/NVO

Novo Nordisk (NOVOB DC) takes legal action against Hims & Hers (HIMS) to protect patients from unsafe, knock-off Wegovy and Ozempic

[MARKET UPDATE] Sterling continues to climb, Cable at a fresh session high, after UK PM Starmer says he will not resign

Iran's Atomic Chief Eslami says Tehran could dilute its highly enriched uranium if all sanctions are lifted, ISNA reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Novo Nordisk is asking the court to permanently ban Hims from selling unapproved, compounded drugs that infringe our patents, and is seeking to recover damages 
Context

This move could have implications for Hims' market position and potentially impact consumer confidence in their offerings, while reinforcing Novo Nordisk's intellectual property rights and market exclusivity.

Related headlines

The whole workspace, free to try.

Try it free